The Food and Drug Administration yesterday alerted health care providers and the public to an increased risk of heart-related death from a drug used to treat gout, a type of arthritis in adults. Preliminary results from a safety clinical trial of the drug febuxostat (Uloric) show an increased risk of heart-related death compared to the gout medicine allopurinol, FDA said. “Health care professionals should consider this safety information when deciding whether to prescribe or continue patients on febuxostat,” the agency said. Febuxostat drug labels already carry a warning about cardiovascular events because the drug showed a higher rate of heart-related problems in clinical trials conducted before approval. “We are continuing to evaluate this safety issue and will update the public when we have more information,” FDA said. “We urge health care professionals and patients to report side effects involving febuxostat or other medicines to the FDA MedWatch program.”

Related News Articles

Insights and Analysis
Also in this roundup of nursing news: two nurses save the life of a man struck by an SUV; and executive moves in the field.
Insights and Analysis
Also in this weekly roundup of nursing news: nurse leaders’ characteristics influence patient outcomes; a nurse helps a man who suffered a heart attack at the…
Headline
The Department of Health and Human Services Friday released guidance on its priorities for physician-focused payment models to help stakeholders who are…
Insights and Analysis
Also in this weekly roundup of nursing news: a talking robot may be poised to become an asset to nurses, and family-centered care interventions may reduce…
Insights and Analysis
Also in this weekly roundup of nursing news: A cancer survivor follows in the footsteps of the nurses who took care of her, and a small study suggests that…
Insights and Analysis
Also in this week’s roundup of nursing news: More to nurse staffing ratios than meets the eye; the media doesn’t show the full scope of nursing; and hospitals…